Delayed Initial Radioiodine Adjuvant Therapy Does Affect Biochemical Response in Intermediate- to High-Risk Differentiated Thyroid Cancer

被引:8
|
作者
Yu, Feng [1 ]
Li, Xue [1 ]
Ji, Yanhui [1 ]
Tan, Jian [1 ]
Zhang, Guizhi [1 ]
Wang, Peng [1 ]
He, Yajing [1 ]
Wang, Renfei [1 ,2 ]
机构
[1] Tianjin Med Univ Gen Hosp, Dept Nucl Med, Tianjin, Peoples R China
[2] Shanghai Jiao Tong Univ Affiliated Peoples Hosp 6, Dept Nucl Med, Shanghai, Peoples R China
来源
关键词
Differentiated thyroid carcinoma (DTC); Radioiodine therapy; timing; therapy response; prognosis; RADIOACTIVE IODINE THERAPY; REMNANT ABLATION; SURVIVAL; THYROGLOBULIN; RECURRENCE; CARCINOMA; OUTCOMES; NODULES; IMPACT;
D O I
10.3389/fendo.2021.743310
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
BackgroundThere are no definite recommendations on the optimal time of initiating radioactive iodine (RAI) therapy for differentiated thyroid cancer (DTC) patients in current relevant guidelines. This study aimed to investigate the relationship between the timing of initiating radioiodine adjuvant therapy (RAT) and the clinical outcomes based on dynamic follow-ups and assessments in intermediate- to high-risk DTC patients. MethodsA total of 206 patients with intermediate- to high-risk DTC receiving RAT of 150 mCi were retrospectively reviewed. According to the time interval (TI: between thyroidectomy and initial RAT), the patients were divided into 2 groups: Group 1: TI < 3 months (n=148), and Group 2: TI >= 3 months (n=58). The RAT therapy response was evaluated as excellent response (ER), indeterminate response (IDR), biochemical incomplete response (BIR), structural incomplete response (SIR). The univariate and multivariate analyses were conducted to screen out factors associated with incomplete response (IR= BIR+SIR). Finally, the prognostic nomogram was used to explain IR rates as a valuable tool in clinical practice. ResultsResponse to initial RAT was significantly different between 2 groups during dynamic follow-ups (all P<0.05). Group 2 had significantly lower ER rates (37.9 vs 63.5, 52.0 vs 73.9, 64.4 vs 80.3, all P<0.05, respectively) and higher IR rates (39.7 vs 14.9, 36.0 vs 9.7, 12.2 vs 3.9, all P<0.05, respectively) than group 1 during dynamic follow-ups. By univariate and multivariate analyses, prolonged TI (HR: 6.67, 95%CI: 2.241-19.857, P=0.001), soft tissue invasion (HR: 7.35, 95%CI: 1.624-33.296, P=0.010), higher sTg (HR: 7.21, 95%CI: 1.991-26.075, P=0.003) were manifested to be independent risk factors for IR. The nomogram showed that soft tissue invasion, sTg, and TI were the top 3 contributors to the IR. ConclusionsEarly RAT is associated with greater biochemical response but has no impact on SIR. Delayed initial RAT (>= 3 months after thyroidectomy) related to IR in intermediate- to high-risk DTC.
引用
收藏
页数:9
相关论文
共 50 条
  • [21] Value of Diagnostic Radioiodine Whole-Body Scanning After Initial Therapy in Patients with Differentiated Thyroid Cancer at Intermediate and High Risk for Recurrence
    Rosario, Pedro Weslley
    Furtado, Mariana de Souza
    Campos Mineiro Filho, Augusto Flavio
    Lacerda, Rafaela Xavier
    Calsolari, Maria Regina
    [J]. THYROID, 2012, 22 (11) : 1165 - 1169
  • [22] Intermediate- to high-risk prostate cancer patient treated with radiation therapy
    Raben, David
    Lucia, Scott
    Glode, Michael
    Crawford, E. David
    Kavanagh, Brian
    Raben, Adam
    Ayres, Jennifer
    [J]. ONCOLOGY-NEW YORK, 2004, 18 (09): : 1105 - 1110
  • [23] Localized intermediate- to high-risk prostate cancer
    Tritschler, S.
    Ganswindt, U.
    Stief, C. G.
    [J]. UROLOGE, 2016, 55 (03): : 318 - +
  • [24] APPLICABILITY ANALYSIS OF FOCAL THERAPY TO INTERMEDIATE- AND HIGH-RISK PROSTATE CANCER
    Matsuoka, Yoh
    Numao, Noboru
    Saito, Kazutaka
    Tanaka, Hiroshi
    Inoue, Masaharu
    Ito, Masaya
    Yoshida, Soichiro
    Yokoyama, Minato
    Ishioka, Junichiro
    Fujii, Yasuhisa
    Kihara, Kazunori
    [J]. JOURNAL OF UROLOGY, 2016, 195 (04): : E195 - E195
  • [25] Utility of FDG PET at the Initial Radioiodine Therapy in Differentiated Thyroid Cancer
    Matsuo, Mioko
    Baba, Shingo
    Hashimoto, Kazuki
    Isoda, Takuro
    Kitamura, Yoshiyuki
    Kogo, Ryunosuke
    Jiromaru, Rina
    Hongo, Takahiro
    Manako, Tomomi
    Nakagawa, Takashi
    [J]. ANTICANCER RESEARCH, 2023, 43 (01) : 183 - 190
  • [26] Outcome of radioiodine therapy in risk stratified differentiated thyroid cancer
    Pradhan, Prasanta
    Mammoottil, Alen
    Gambhir, Sanjay
    Mishra, Saroj
    Mishra, Anjali
    [J]. JOURNAL OF NUCLEAR MEDICINE, 2019, 60
  • [27] Clinical outcome of postoperative radioiodine therapy with high dose and low dose in intermediate risk differentiated thyroid cancer patients
    Jeong, J.
    Kong, E.
    Jeong, S.
    Lee, S.
    Lee, J.
    Chun, K.
    Ahn, B.
    [J]. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2016, 43 : S161 - S161
  • [28] Postoperative thyroid remnants for differentiated thyroid cancer may not affect the outcome of high-dose radioiodine therapy
    Pan, Liqin
    Chen, Yanying
    Li, Sixiao
    Ouyang, Wei
    Feng, Huijuan
    Wu, Juqing
    Chen, Pan
    Deng, Yuying
    Wang, Jing
    Luo, Jiaxin
    Xian, Jialan
    [J]. ORAL ONCOLOGY, 2020, 104
  • [29] European approach to adjuvant treatment of intermediate- and high-risk malignant melanoma
    Eggermont, AMM
    Gore, M
    [J]. SEMINARS IN ONCOLOGY, 2002, 29 (04) : 382 - 388
  • [30] Development and validation of a lung metastasis-predicting Nomogram for intermediate- to high-risk differentiated thyroid carcinoma patients
    Yu, Feng
    Ma, Wenhui
    Yang, Zhiping
    Yang, Weidong
    Wang, Jing
    [J]. JOURNAL OF NUCLEAR MEDICINE, 2023, 64